Susquehanna International Group, LLP Cyma Bay Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $1.97 Million - $3.81 Million	-155,800 Reduced 50.75%	151,200 $3.57 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $3.18 Million - $5.15 Million	292,500 Added 2017.24%	307,000 $4.58 Million
Q2 2023 Aug 11, 2023	SELL	$7.47 - $10.95 $162,099 - $237,614	-21,700 Reduced 59.94%	14,500 $158,000
Q1 2023 May 16, 2023	BUY	$5.88 - $9.59 $119,952 - $195,636	20,400 Added 129.11%	36,200 $315,000
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $10,626 - $20,691	-3,300 Reduced 17.28%	15,800 $99,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $13,850 - $21,250	-5,000 Reduced 20.75%	19,100 $67,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.